Larimar Therapeutics (LRMR) Projected to Post Quarterly Earnings on Wednesday

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Larimar Therapeutics to post earnings of ($0.49) per share for the quarter.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, analysts expect Larimar Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Larimar Therapeutics Trading Down 0.6%

LRMR stock traded down $0.02 during midday trading on Friday, hitting $3.44. The company had a trading volume of 1,159,970 shares, compared to its average volume of 1,002,577. The stock has a market cap of $220.26 million, a price-to-earnings ratio of -2.31 and a beta of 0.86. Larimar Therapeutics has a 52 week low of $1.61 and a 52 week high of $9.50. The stock's 50 day moving average price is $2.96 and its 200 day moving average price is $2.76.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on LRMR shares. Citigroup reaffirmed a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Wedbush decreased their price target on shares of Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research note on Tuesday, June 24th. Finally, Guggenheim reissued a "buy" rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $18.50.

Institutional Investors Weigh In On Larimar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new position in Larimar Therapeutics in the 1st quarter valued at $241,000. Rhumbline Advisers grew its holdings in shares of Larimar Therapeutics by 15.7% in the first quarter. Rhumbline Advisers now owns 65,018 shares of the company's stock worth $140,000 after purchasing an additional 8,818 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Larimar Therapeutics during the 1st quarter valued at about $113,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.